Journal: Clinica chimica acta; international journal of clinical chemistry

Article Title: Novel LC-MS/MS method for plasma vancomycin: comparison with immunoassays and clinical impact.

doi: 10.1016/j.cca.2014.12.012

Figure Lengend Snippet: Fig. 1. A) Chromatogram of a low QC (3.0 mg/L vancomycin); B) chromatogram of a high QC (30.0 mg/L vancomycin); C) chromatogram of a patient sample (14.3 mg/L) vancomycin.

Article Snippet: Vancomycin HCl was purchased from Toronto Research Chemicals (Toronto, Canada).

Techniques:

Journal: Scientific Reports

Article Title: Repurposing antibacterial drugs identifies ridinilazole and CRS3123 as promising candidates against vancomycin-resistant enterococci

doi: 10.1038/s41598-025-29583-1

Figure Lengend Snippet: Time kill assay of ridinilazole, CRS3123 and linezolid at 5× and 10× MIC, against E. faecium NR-31,909. Samples treated with DMSO were used as negative control. The results are given as means ± SD ( n = 3; data without error bars indicate that the SD is too small to be seen).

Article Snippet: Linezolid (Selleck Chemicals) and vancomycin hydrochloride (Gold Biotechnology) were all purchased from commercial suppliers.

Techniques: Time-Kill Assay, Negative Control

Journal: Scientific Reports

Article Title: Repurposing antibacterial drugs identifies ridinilazole and CRS3123 as promising candidates against vancomycin-resistant enterococci

doi: 10.1038/s41598-025-29583-1

Figure Lengend Snippet: In vivo efficacy of ridinilazole and CRS3123 against Enterococcus infection in the C. elegans model. C. elegans were infected with E. faecium NR-31,909 or E. faecalis ATCC 29,212. After infection, 30 worms were treated with ridinilazole, CRS3123, or linezolid. After 24 h, worms were lysed, and bacteria were plated to determine CFU counts. In E. faecium -infected worms, CRS3123 and linezolid reduced bacterial burden by approximately 3.8 and 3.5 log units, respectively, while ridinilazole produced a 2.5 log reduction. In E. faecalis -infected worms, CRS3123 and linezolid resulted in 1.8 and 1.5 log reductions, whereas ridinilazole showed no significant effect. Results are expressed as means from three biological replicates ± standard deviation. Statistical analyses were determined by one-way ANOVA with post hoc testing (* p < 0.01, ** p < 0.005, *** p < 0.0001).

Article Snippet: Linezolid (Selleck Chemicals) and vancomycin hydrochloride (Gold Biotechnology) were all purchased from commercial suppliers.

Techniques: In Vivo, Infection, Bacteria, Produced, Standard Deviation

Journal: ACS Omega

Article Title: Electrospun Chitosan-Based Nanofibrous Coating for the Local and Sustained Release of Vancomycin

doi: 10.1021/acsomega.3c08113

Figure Lengend Snippet: Microscopic characterization of nanofibrous mat SEM images of formulations of vancomycin nanofibers at magnifications of 5000x and corresponding size distribution histograms. (A) Formulation with chitosan in HFIP. (B) Formulation with chitosan and PVA in acetic acid solution (F2). (C) Formulation with chitosan and PEO in acetic acid solution (F4). Chitosan alone proved to be extremely difficult to spin due to its limited solubility (A), and for this reason, the addition of a copolymer such as PVA and PEO was explored to enhance the electrospinnability properties of chitosan (B,C).

Article Snippet: Vancomycin HCl was purchased from Tocris Bioscience (Minneapolis).

Techniques: Formulation, Solubility